Epitope selection and development of peptide based vaccines to treat cancer
- 31 December 1995
- journal article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 6 (6) , 329-336
- https://doi.org/10.1016/1044-579x(95)90002-0
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.Journal of Clinical Investigation, 1995
- A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3European Journal of Immunology, 1994
- Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell LinesScience, 1994
- Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 moleculesCell, 1993
- Dominance and Crypticity of T Cell Antigenic DeterminantsAnnual Review of Immunology, 1993
- Peptides Naturally Presented by MHC Class I MoleculesAnnual Review of Immunology, 1993
- Tumor AntigensAnnual Review of Immunology, 1992
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986
- Cytolytic T LymphocytesAnnual Review of Immunology, 1983